The UJI effectively tests molecules capable of improving immunity or reducing inflammation of the tumour ecosystem and blocking the growth of cancer cells



[Valencià](/upo/rest/publicacion/idioma/ca?urlRedirect=https://www.uji.es/com/investigacio/arxiu/noticies/2025/4/generacio-coneixement-2021-lluita-microambient-tumoral/&url=/com/investigacio/arxiu/noticies/2025/4/generacio-coneixement-2021-lluita-microambient-tumoral/&urlRedirect=https://www.uji.es/com/investigacio/arxiu/noticies/2025/4/generacio-coneixement-2021-lluita-microambient-tumoral/ "Cambiar idioma a català")
[Español](/upo/rest/publicacion/idioma/es?urlRedirect=https://www.uji.es/com/investigacio/arxiu/noticies/2025/4/generacio-coneixement-2021-lluita-microambient-tumoral/&url=/com/investigacio/arxiu/noticies/2025/4/generacio-coneixement-2021-lluita-microambient-tumoral/&urlRedirect=https://www.uji.es/com/investigacio/arxiu/noticies/2025/4/generacio-coneixement-2021-lluita-microambient-tumoral/ "Cambiar idioma a español")
[English](#0)

Mobile menu

* [Profile](#0)
  + [Future students](/perfils/futurs/)
  + [UJI students](/perfils/estudiantat/uji/)
  + [PDI-PI](/perfils/pdipas/base/pdi/)
  + [PTGAS](/perfils/pdipas/base/pas/)
  + [AlumniSAUJI](/serveis/alumnisauji/)
  + [Companies and institutions](/perfils/empresa/)
* [Tools](#0)
  + [Virtual Classroom](https://aulavirtual.uji.es/)
  + [CAU](https://cau.uji.es/)
  + [Directory](//www.uji.es/institucional/contacta/)
  + [Gmail](http://gmail.uji.es/)
  + [Intranet (IGLU)](//www.uji.es/upo/rest/iglu/)
  + [Virtual Office](/seu/)
  + [Academic information (SIA)](http://sia.uji.es/)
  + [Others](//www.uji.es/serveis/scp/eines/)
* [Valencià](/upo/rest/publicacion/idioma/ca?urlRedirect=https://www.uji.es/com/investigacio/arxiu/noticies/2025/4/generacio-coneixement-2021-lluita-microambient-tumoral/&url=/com/investigacio/arxiu/noticies/2025/4/generacio-coneixement-2021-lluita-microambient-tumoral/&urlRedirect=https://www.uji.es/com/investigacio/arxiu/noticies/2025/4/generacio-coneixement-2021-lluita-microambient-tumoral/ "Cambiar idioma a català")
  [Español](/upo/rest/publicacion/idioma/es?urlRedirect=https://www.uji.es/com/investigacio/arxiu/noticies/2025/4/generacio-coneixement-2021-lluita-microambient-tumoral/&url=/com/investigacio/arxiu/noticies/2025/4/generacio-coneixement-2021-lluita-microambient-tumoral/&urlRedirect=https://www.uji.es/com/investigacio/arxiu/noticies/2025/4/generacio-coneixement-2021-lluita-microambient-tumoral/ "Cambiar idioma a español")
  [English](#0)

[# Universitat Jaume I](/)

* [# Universitat Jaume I](/)
* [Profile](#0)
  + [Future students](/perfils/futurs/)
  + [UJI students](/perfils/estudiantat/uji/)
  + [PDI-PI](/perfils/pdipas/base/pdi/)
  + [PTGAS](/perfils/pdipas/base/pas/)
  + [AlumniSAUJI](/serveis/alumnisauji/)
  + [Companies and institutions](/perfils/empresa/)
* [Tools](#0)
  + [Virtual Classroom](https://aulavirtual.uji.es/)
  + [CAU](https://cau.uji.es/)
  + [Directory](//www.uji.es/institucional/contacta/)
  + [Gmail](http://gmail.uji.es/)
  + [Intranet (IGLU)](//www.uji.es/upo/rest/iglu/)
  + [Virtual Office](/seu/)
  + [Academic information (SIA)](http://sia.uji.es/)
  + [Others](//www.uji.es/serveis/scp/eines/)
* [Studies](/mapa/estudis/)
  + [Studies](/mapa/estudis/)
  + [Bachelor’s degrees](/estudis/)
  + [University master’s degrees](/estudis/?p_estudio=m)
  + [Doctoral studies](/estudis/oferta/doctorat/)
  + [Lifelong learning](/estudis/base/formacio-permanent/)
* [Research and innovation](/investigacio/)
  + [Research and innovation](/investigacio/)
  + [Research portal](/investigacio/)
  + [Innovation](/innovacio/)
  + [Doctoral studies](/centres/escola-doctorat/)
  + [HRS4R](/investigacio/hrs4r/)
* [International](/internacional/)
  + [International](/internacional/)
  + [International Students](/internacional/base/estudiantat/estudiantado-internacional/)
  + [Exchange Programmes](/serveis/ori/base/programes-intercanvi/)
  + [Study Abroad](/internacional/base/study-abroad/)
* [UJI](/mapa/uji/)
  + [UJI](/mapa/uji/)
  + [Get to know the UJI](/mapa/uji/coneix-uji/)
  + [Structure and organisation](/institucional/estructura/)
  + [Strategy and quality](/institucional/estrategia/)
  + [Transparency](/transparencia/)
  + [Public integrity](/transparencia/liniaetica/)
  + [News](/actualitat/)
  + [Contact the UJI](/institucional/contacta/)
* [University life](/mapa/vida-universitaria/)
  + [University life](/mapa/serveis/)
  + [Library](/serveis/cd/)
  + [Campus](/mapa/uji/coneix-uji/campus/)
  + [Culture](/cultura/)
  + [Sports](/esports/)
  + [InfoCampus](/serveis/infocampus/)

[UJI](/)
[News](/com/sumari/noticies/)

## The UJI effectively tests molecules capable of improving immunity or reducing inflammation of the tumour ecosystem and blocking the growth of cancer cells

11/04/2025 |
SCP

Compartir

Compartir

×

Linkedin

BlueSky

Facebook

Mastodon

Whatsapp

Gmail

Imprimir

* [![Chemistry for medicine generacio-coneixement-2021-lluita-microambient-tumoral Quimica_per_a_la_medicina_25DLL20](/com/investigacio/arxiu/noticies/2025/4/generacio-coneixement-2021-lluita-microambient-tumoral/Quimica_per_a_la_medicina_25DLL20.jpg)](#)

During tumour development, cancer cells do not exist in isolation; rather, they interact with a diverse array of cellular and non-cellular components that collectively form a unique ecosystem known as the tumour microenvironment (TME). This highly complex environment provides optimal conditions for tumour growth and progression, playing a pivotal role in both cancer development and treatment response.

In recent years, growing recognition of the TME’s significance as a biological target—particularly its role in tumour resistance—has positioned it at the forefront of research efforts. Understanding its mechanisms has become essential for developing innovative therapeutic strategies aimed at overcoming resistance and improving treatment efficacy.

A team from the Universitat Jaume I in Castelló, led by researcher Eva Falomir Ventura, coordinator of the Chemistry for Medicine (JMC) group, has achieved promising results in testing molecules previously designed and synthesised by the same group. These molecules have the potential to block cancer cell growth by altering key microenvironment properties, such as immunity, inflammation, and the formation of new blood vessels.

In the different studies they are carrying out in the project ‘Development of new multi-target anti-cancer agents with a potential disruptive effect on the tumour microenvironment’, funded by the State Research Agency of the 2021-2023 State Plan for Scientific, Technical and Innovation Research, which ends in September 2025, the research team has synthesised and biologically evaluated more than a hundred small organic molecules of the aryltriazole and tetrazole types, of the styrene and styrylurea or styrylcarbamate derivatives types.

Preliminary results have shown, for example, that compounds with a tetrazole or triazole template are not at all toxic in themselves, but have the capacity to block the growth of cancer cells when these are in the presence of defensive cells such as T cells or monocytes. It has been proven that, in vitro, some of these compounds are capable of modulating inflammation, reducing the presence of pro-inflammatory cytokines in MT and stimulating immunological capacity, activating defensive cells against tumours. In addition, some of them have been shown to be selective in differentiating cancer cells from healthy cells and promoting apoptosis (programmed death) of bad cells.

In some of these compounds designed by the group, in vitro experimentation suggests that they are molecules with inhibitory capacities on two of the proteins that play a crucial role in the spread of cancer (VEGFR-2, responsible for the creation of new blood vessels and the spread of cancer cells, and PD-L1, which helps cancer to evade the immune system). Some of these molecules have been shown to increase the activity of CD8+ T immune cells, which are crucial in the fight against this disease.

These findings suggest the potential of these new compounds, although further research is needed to explore the detailed mechanisms of action, optimise their potency and selectivity, and evaluate their efficacy in preclinical and clinical models before they can be developed into therapeutic agents for the treatment of cancer.

During the development of the project, the research team (made up of Eva Falomir, Pedro Miguel Carda, Amelia Bou Puerto, Raquel Gil Edo, Alberto Pla López and Celia Martín Beltrán) has opened up new channels of collaboration with other groups at the UJI (SUPRAMAT, GROC) for the application of materials such as hydrogels or nanoparticles, Sustainable and Supramolecular Chemistry, Computational Biochemistry, MicroBIO and Biochemistry and Biotechnology, who are also studying these compounds and their relationship with biological targets.

Cooperation has also been extended to other European centres, such as the Medical School of Edinburgh (United Kingdom), to carry out more exhaustive studies on the influence of the compounds on onco-inflammatory processes, or the University of Leuven (Belgium), which analyses the antiviral and antitumour properties of the compounds obtained at the UJI.

In order to carry out the analysis and study of all the compounds and elements and their interaction with human cancer cell lines (colon, breast or lung), in addition to the group's own laboratories, the NMR, mass spectrometry and flow cytometry facilities of the UJI's Central Scientific Instrumentation Service, which has an advanced scientific infrastructure, have been used.

The research is funded by grant PID2021-126277OB-100 from MICIU/AEI (<https://doi.org/10.13039/501100011033>) and ERDF, EU, as well as by the Ministry of Economy and Competitiveness (project RTI2018-097345-B-I00) and the Universitat Jaume I (project UJI-B2021-46). It also benefits from the support of the European Union–Next Generation EU, the Public State Employment Service (SEPE), and the Ministry of Labour and Social Economy through contract 20881 under the Investigo Programme, as part of the Recovery, Transformation, and Resilience Plan.

**Articles**

Amelia Bou Puerto, Pedro Miguel Carda, Eva Falomir. Styryl carbamate backbones for the discovery of TME-disrupting agents. Results Chem. 2024, 7, 101372-101382, doi:10.1016/j.rechem.2024.101372

Raquel Gil Edo, Sara Espejo Jurado, Eva Falomir, Pedro Miguel Carda. Synthesis and Biological Evaluation of Potential Oncoimmunomodulator Agents. Int. J. Mol. Sci. 2023, 24, 2614-2634, doi: 10.3390/ijms24032614

Alberto Pla López, Pedro Miguel Carda, Eva Falomir. Tetrazole derivatives as potent immunomodulatory agents in tumor microenvironment. Biomed. Pharmacother. 2023, 169, 115668-115680, doi: 10.1016/j.biopha.2023.115668

Raquel Gil Edo, Santiago Royo, Eva Falomir, Pedro Miguel Carda. Unveiling the Potential of BenzylethyleneAryl–Urea Scaffolds for the Design of New Onco Immunomodulating Agents. Pharmaceuticals 2023, 16, 808-822; doi: 10.3390/ph16060808.

Raquel Gil Edo, German Hernández-Ribelles, Santiago Royo, Natasha Thawait, Alan Serrels, Pedro Miguel Carda, Eva Falomir. Exploring BenzylethoxyAryl Urea Scaffolds for Multitarget Immunomodulation Therapies. Int. J. Mol. Sci. 2023, 24, 8582-8598; doi:10.3390/ijms24108582

Alberto Pla López, Paula Martínez Colomina, Laura Cañada García, Laura Fuertes Monge, Jose C. Orellana Palacios, Alejandro Valderrama Martínez, Marikena Pérez Sosa, Pedro Miguel Carda, Eva Falomir. Aryl Azoles Based Scaffolds for Disrupting Tumor Microenvironment Bioorg. Med. Chem. 2023, 95, 117490-117504, doi: 10.1016/j.bmc.2023.117490

Alberto Pla López, Raquel Castillo Solsona, Rocío Cejudo Marín, Olaya García-Pedrero, Mariam Bakir-Laso, Eva Falomir, Pedro Miguel Carda. Synthesis and Biological Evaluation of Small Molecules as Potential Anticancer Multitarget Agents Int. J. Mol. Sci. 2022, 23, 7049-7068, doi:10.3390/ijms23137049

Information provided by:
[Communication and Publications Service](/serveis/scp/)

About us

[Home](/com/investigacio/cienciauji/)
[UCC+I](/serveis/scp/ucc/)

Research dissemination

[Ciència TV blog](/com/investigacio/arxiu/ciencia-uji-tv/)
[Ciència UJI newsletter](/com/investigacio/arxiu/ciencia-uji/)
[Horizon Europe newsletter](/com/investigacio/docs/butlleti-horizon-europe/)
[Comboi, a trip through science](/com/investigacio/docs/podcast-comboi-viatge-per-la-ciencia/)
[Scientific news](/com/investigacio/sumari/noticies/ )
[Easy reading news](/com/investigacio/docs/noticies-de-lectura-facil)
[News magazine. Research](/com/revista/tematica/investiga/)
[Radio](http://www.radio.uji.es/programa.php?id=46 )

Scientific divulgation

[Experimenta UJI](/com/investigacio/docs/experimenta-uji/)
[Innobar, con b de bar (Espaitec)](https://espaitec.uji.es/podcast-innobar-con-b-de-bar/)
[Magazine «Humanes i Socials»](https://humanesisocials.uji.es)
[H2020 Projects](/com/investigacio/docs/butlleti-h2020/)
[Projects and papers COVID-19](/com/investigacio/docs/estudis-articles-covid-19/)
[Research pitches](/com/investigacio/research-pitches/)
[The Conversation](/com/investigacio/docs/the-conversation/)
[UJI Divulga (Onda Cero)](/com/investigacio/docs/uji-divulga-onda-cero/)
[Scientific vocabulary](/com/investigacio/docs/vocabulari-cientific/)

Projects and studies

[Projects and studies](/serveis/scp/ucc/projectes/)

Resources of interest

[Divulgateca](http://www.divulgateca.es)

External networks

[CRUE](https://www.crue.org/)
[FECYT](https://www.fecyt.es/es/info/que-son)
[RUVID](https://ruvid.org/)



Useful links

[University card](http://www.carnet.uji.es/)

[Multimedia catalogue](http://jecom.uji.es/)

[University press](/serveis/scp/publ/)

[Web map](//www.uji.es/mapa/)

[Educational model](//www.uji.es/institucional/estrategia/modeleducatiu/)

[Language Observatory](/serveis/ol/)

[Open Knowledge Portal](/serveis/cd/bib/pco/)

[UJI shop](http://www.tenda.uji.es/)

[Security and privacy center](https://www.uji.es/organs/ouag/sg/docs/politiques/gen/)
|
[Website legal notice](https://www.uji.es/comu/avislegal/avislegalicondicions/)
|
[Accessibility policy](https://www.uji.es/serveis/ura/base/accessibilitat/)

Information and queries:
[UJI suggestion box](/comu/forms/bustia)

Universitat Jaume I CIF: Q-6250003-H Av. Vicent Sos Baynat, s/n 12071
Castellón de la Plana,
España

Tel.: +34 964 72 80 00